• Lutte contre les cancers

  • Observation

  • Estomac

Gastrointestinal metastases in renal cell carcinoma: a retrospective multicenter GETUG (Groupe d’Étude des Tumeurs Uro-Génitales) study

Menée en France à partir de données portant sur 74 patients présentant des métastases gastro-intestinales provenant d'un carcinome à cellules rénales (âge médian au diagnostic des métastases : 69 ans), cette étude multicentrique rétrospective analyse les caractéristiques des métastases et des patients, les stratégies thérapeutiques et le pronostic associé

Background: Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood. Objectives: To report clinical presentations, patient characteristics, therapeutic strategies, and prognosis of GIMs from RCC. Methods: We retrospectively collected data from RCC patients presenting GIMs, in 10 French GETUG centers, between 2000 and 2021. Results: We identified 74 patients with 87 GIMs, mostly gastric or duodenal. The median age at GIM diagnosis was 69 years and 76% of patients already had other metastases. GIMs occurred after a median duration of 5.4 years (IC95%=[4.2-7.1]) and 1.9 years (IC95%=[1.2-3.8]) from RCC diagnosis and first metastasis, respectively. GIMs were symptomatic in 52 patients (70%), with anemia in 41 patients (55%) and/or gastrointestinal bleeding in 31 patients (42%). Only 22 asymptomatic patients (30%) were fortuitously diagnosed. GIM management consisted of systemic treatment only in 29 GIMs (33%), local treatment only in 23 GIMs (26%), and both local and systemic treatment in 18 GIMs (21%). For 17 GIMs (20%), there was no therapeutic modification. After diagnosis of GIM, median overall survival was 19 months. Conclusion: We report the largest retrospective cohort of GIMs in RCC patients. They should be suspected in case of anemia or gastrointestinal bleeding in any patient with a history of RCC. Their management varies widely depending on their location in the digestive tract and whether or not they are symptomatic.

European Journal of Cancer 2024

View the bulletin